Reckitt, Generics Makers Settle Mucinex Antitrust Case

Law360, Los Angeles (November 29, 2017, 10:15 PM EST) -- Reckitt Benckiser Inc. has reached a settlement with a generic-drug maker that had accused the British company of unfairly cutting out competition for an extended-release version of Mucinex by violating a patent infringement settlement agreement they'd struck, according to a judgment Tuesday ending the Pennsylvania federal court case.

Reckitt resolved a two-year dispute with Mutual Pharmaceuticals Co. and related companies over whether Reckitt violated a 2007 settlement agreement in a patent suit over the formula that backs Mucinex, called extended-release guaifenesin, after nearly a year of negotiations between the companies, according to an order cementing a stipulation by the parties to...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!